Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces Earnings Results, Misses Expectations By $3.23 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Tuesday. The company reported ($3.42) EPS for the quarter, missing the consensus estimate of ($0.19) by ($3.23), FiscalAI reports. The company had revenue of $1.09 million for the quarter, compared to analysts’ expectations of $0.74 million.

Armata Pharmaceuticals Stock Performance

ARMP opened at $10.56 on Thursday. Armata Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $16.34. The firm has a 50 day moving average price of $8.97 and a 200 day moving average price of $6.61. The company has a market cap of $386.81 million, a PE ratio of -2.19 and a beta of 1.38.

Wall Street Analysts Forecast Growth

ARMP has been the subject of several research reports. HC Wainwright boosted their price objective on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. JonesTrading assumed coverage on Armata Pharmaceuticals in a research report on Monday, January 5th. They issued a “buy” rating and a $15.00 target price on the stock. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

Institutional Investors Weigh In On Armata Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $284,000. OMERS ADMINISTRATION Corp purchased a new stake in Armata Pharmaceuticals during the 4th quarter worth $177,000. Renaissance Technologies LLC boosted its position in Armata Pharmaceuticals by 65.9% during the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after purchasing an additional 27,200 shares during the period. Millennium Management LLC acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at $164,000. Finally, Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at $108,000. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.